OKYO Pharma Announces Participation in May 2024 Investor Conferences

Rhea-AI Summary

OKYO Pharma (NASDAQ: OKYO) is set to participate in two upcoming investor conferences in May 2024 to present its innovative ocular therapies for inflammatory dry eye disease and anterior ocular segment diseases. The company will be presenting at the Aegis Capital Virtual Healthcare Conference on May 8, 2024, and at the Citizens JMP Securities Life Sciences Conference on May 13, 2024. Gary Jacob, PhD, the Chief Executive Officer, will be the presenter at both conferences.

LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced upcoming presentations at two investor conferences in May 2024.

Conference: Aegis Capital Virtual Healthcare Conference
Date: Wednesday May 8, 2024, 11 AM EST
Location: Virtual
Presenter: Gary Jacob, PhD, Chief Executive Officer

Conference: Citizens JMP Securities Life Sciences Conference
Date: Monday May 13, 2024, 10:30 AM EST
Location: New York, NY
Presenter: Gary Jacob, PhD, Chief Executive Officer

About OKYO

OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.

Enquiries:

OKYO Pharma Limited	Gary S. Jacob, Chief Executive Officer	917-497-7560
Business Development & Investor Relations	Paul Spencer	+44 (0)20 7495 2379

FAQ

When is OKYO Pharma participating in investor conferences in May 2024?

OKYO Pharma is participating in two investor conferences in May 2024: Aegis Capital Virtual Healthcare Conference on May 8, 2024, and Citizens JMP Securities Life Sciences Conference on May 13, 2024.

What is the focus of OKYO Pharma's ocular therapies?

OKYO Pharma focuses on developing innovative ocular therapies for inflammatory dry eye disease (DED) and anterior ocular segment diseases including neuropathic corneal pain (NCP).

Who will be presenting at the investor conferences for OKYO Pharma?

Gary Jacob, PhD, the Chief Executive Officer of OKYO Pharma, will be the presenter at both the Aegis Capital Virtual Healthcare Conference and Citizens JMP Securities Life Sciences Conference.